🏆 Deal of the Month · January 2025
Bioptimus raised USD 41 million in a Series A round in January 2025; the company's valuation was not disclosed. The round was backed by Cathay Innovation. The funding will support Bioptimus in advancing its universal AI foundation models for biology and expanding its research capabilities across biomedicine.
Bioptimus — key deal facts
| Company | Bioptimus |
| Founded | 2024 |
| Headquarters | Paris, France |
| Amount raised | USD 41m |
| Valuation | Valuation Remains Undisclosed |
| Round | Series A |
| Investors | Cathay Innovation |
| Sectors | Biotechnology |
Who invested in Bioptimus?
Cathay Innovation led the Series A investment in Bioptimus. Cathay Innovation is a global venture fund with strong cross-border reach across Europe, Asia, and the United States, making it a strategically relevant backer for a French deep-tech company targeting international biomedical markets. No additional co-investors have been disclosed in connection with this round.
What does Bioptimus do?
Bioptimus is a Paris-based biotechnology company founded in 2024 that builds universal AI foundation models designed to integrate biological data across scales — from molecules and cells to tissues and whole organisms. Its flagship product, H-Optimus-1, is a foundation model for histology trained on more than one million whole-slide images; it outperforms existing models in tissue classification, tumour grading, and biomarker prediction across 50 organs. The company was co-founded by Dr. Jean-Philippe Vert, formerly a research lead at Google Brain and Chief R&D Officer of Owkin, alongside other scientists from Google DeepMind and Owkin. Bioptimus had previously raised USD 35 million in seed funding to initiate development of its biomedical and environmental science platform.
Bioptimus valuation & multiples
No existing multiples analysis was provided for this deal, and the post-money valuation has not been disclosed, which precludes any EV/Sales or EV/EBITDA derivation at this stage. As disclosed revenue and EBITDA figures become available, standard biotechnology valuation benchmarks can be applied to contextualise the deal. For reference sector multiples used in comparable biotechnology transactions, visit the Venionaire DealMatrix biotechnology sector multiples pages.
Explore the benchmarks: Series A.
Frequently asked questions
How much did Bioptimus raise in its Series A?
Bioptimus raised USD 41 million in its Series A round, closed in January 2025.
What is Bioptimus's valuation?
Bioptimus's valuation was not disclosed in connection with the Series A round.
Who invested in Bioptimus?
Cathay Innovation invested in Bioptimus's Series A round.
When was Bioptimus founded and where is it based?
Bioptimus was founded in 2024 and is headquartered in Paris, France.
Source: original announcement — read the full report.